CM383 vs Remternetug

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline

CM383

Developed by Keymed Biosciences

Phase 1 in Alzheimer's Diseasemonoclonal antibody
Weak signal

NCT06412185 · Phase 1 · status unknown

This is a randomized, blinded, placebo-controlled study, but it is an early safety study in healthy volunteers rather than patients, and its primary measured outcome is safety rather than a disease outcome. Results have not yet been posted. Its registered primary outcome on ClinicalTrials.gov is "Adverse events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT06619613 (registry estimate)

No aligned efficacy figure on record for this race.

Remternetug

Developed by Eli Lilly

Phase 3 in Alzheimer's Diseasemonoclonal antibody
Partial signal

NCT05463731 · Phase 3 · completed

The study randomized 1,667 participants to remternetug or matching placebo, with participants and investigators blinded during the main treatment period. Its primary endpoint was amyloid plaque clearance measured by PET, a biomarker endpoint, and the registry does not report whether the week-52 comparison was favorable or statistically significant.

Next expected readout: April 2029 · NCT06653153 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCM383Remternetug
CDR-SB, change—Not reported—Not posted · NCT05463731
ADAS-Cog11, change—Not reported—Not posted · NCT05463731
ADCS-ADL, change—Not reported—Not posted · NCT05463731
MMSE, change—Not reported—Not posted · NCT05463731
Amyloid PET, change (centiloids)—Not reported—Not posted · NCT05463731

CDR-SB, change

CM383
—Not reported
Remternetug
—Not posted · NCT05463731

ADAS-Cog11, change

CM383
—Not reported
Remternetug
—Not posted · NCT05463731

ADCS-ADL, change

CM383
—Not reported
Remternetug
—Not posted · NCT05463731

MMSE, change

CM383
—Not reported
Remternetug
—Not posted · NCT05463731

Amyloid PET, change (centiloids)

CM383
—Not reported
Remternetug
—Not posted · NCT05463731
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CM383: no structured comparison results are available for Alzheimer's Disease.

Remternetug: no structured comparison results are available for Alzheimer's Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CM383's landscape · Remternetug's landscape